Zaccardi F, et al. - This meta-analysis was conducted to evaluate the evidence supporting the choice of third-line agents in adults with inadequately controlled type 2 diabetes. With SGLT–2i performing generally better than other drugs, moderate–quality evidence supported the choice of a third–line agent only in patients on metformin combined with sulphonylurea (SU) or thiazolidinedione (TZD). Future guidelines ought to recognise the widely different evidence across possible dual failures in suggesting third-line agents.